$INDP
Indaptus Therapeutics, Inc. Stock $indp

$indp Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223039523 Filed on November 06, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.145M	$2.020M	$1.943M
YoY Change	-1.39%	3.96%	-27.24%
% of Gross Profit
Research & Development	$2.035M	$2.227M	$1.610M
YoY Change	6.42%	38.34%	130.7%
% of Gross Profit
Depreciation & Amortization	$320.00	$0.00	$390.00
YoY Change	0.0%	-100.0%	-11.36%
% of Gross Profit
Operating Expenses	$4.180M	$4.248M	$3.553M
YoY Change	2.27%	19.59%	5.48%
Operating Profit		-$4.248M	-$3.553M
YoY Change		19.59%	5.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$176.9K	$326.0K	$86.18K
YoY Change	-58.99%	278.29%	10321.28%
Pretax Income	-$4.003M	-$3.920M	-$3.466M
YoY Change	9.49%	13.09%	2.95%
Income Tax
% Of Pretax Income
Net Earnings	-$4.003M	-$3.922M	-$3.466M
YoY Change	9.49%	13.16%	2.95%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.47	-$0.42
Diluted Earnings Per Share	-$0.48	-$0.47	-$419.7K
COMMON SHARES
Basic Shares Outstanding	8.401M shares	8.401M shares	8.259M shares
Diluted Shares Outstanding		8.401M shares	8.259M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.36M	$15.96M	$28.46M
YoY Change	-49.45%	-43.92%	-32.01%
Cash & Equivalents	$13.36M	$15.96M	$6.718M
Short-Term Investments	$0.00	$0.00	$21.74M
Other Short-Term Assets	$633.2K	$880.0K	$1.133M
YoY Change	-21.97%	-22.36%	-43.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.00M	$16.84M	$29.59M
YoY Change	-48.63%	-43.08%	-32.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$735.00	$1.055K	$2.340K
YoY Change	-63.6%	-54.91%	-46.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$754.7K	$754.7K	$754.7K
YoY Change	2.23%	0.0%
Total Long-Term Assets	$928.7K	$950.5K	$859.3K
YoY Change	13.31%	10.61%	19700.05%
TOTAL ASSETS
Total Short-Term Assets	$14.00M	$16.84M	$29.59M
Total Long-Term Assets	$928.7K	$950.5K	$859.3K
Total Assets	$14.92M	$17.79M	$30.45M
YoY Change	-46.82%	-41.57%	-30.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$806.0K	$617.3K	$1.246M
YoY Change	-41.52%	-50.47%	-78.44%
Accrued Expenses	$1.968M	$1.750M	$98.63K
YoY Change	2345.06%	1674.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.774M	$2.365M	$2.881M
YoY Change	-19.2%	-17.9%	-50.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$73.35K	$100.0K	$4.950K
YoY Change		1920.2%
Total Long-Term Liabilities	$73.35K	$95.24K	$4.949K
YoY Change		1824.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.774M	$2.365M	$2.881M
Total Long-Term Liabilities	$73.35K	$95.24K	$4.949K
Total Liabilities	$2.847M	$2.460M	$2.886M
YoY Change	-17.07%	-14.74%	-50.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$45.40M	-$41.40M	-$26.30M
YoY Change	51.33%	57.41%	111.17%
Common Stock	$84.01K	$84.01K	$82.59K
YoY Change	0.0%	1.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.08M	$15.33M	$27.57M
YoY Change
Total Liabilities & Shareholders Equity	$14.92M	$17.79M	$30.45M
YoY Change	-46.82%	-41.57%	-30.57%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$4.003M	-$3.922M	-$3.466M
YoY Change	9.49%	13.16%	2.95%
Depreciation, Depletion And Amortization	$320.00	$0.00	$390.00
YoY Change	0.0%	-100.0%	-11.36%
Cash From Operating Activities	-$2.602M	-$3.730M	-$4.602M
YoY Change	17.69%	-18.94%	-18.27%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$570.00	$7.000M	-$2.939M
YoY Change	-99.99%	-338.17%
Cash From Investing Activities	$570.00	$7.000M	-$2.939M
YoY Change	-99.99%	-338.17%	178024.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.602M	-3.730M	-4.602M
Cash From Investing Activities	570.0	7.000M	-2.939M
Cash From Financing Activities			0.000
Net Change In Cash	-2.602M	3.270M	-7.541M
YoY Change	-189.46%	-143.37%	-120.44%
FREE CASH FLOW
Cash From Operating Activities	-$2.602M	-$3.730M	-$4.602M
Capital Expenditures			$0.00
Free Cash Flow			-$4.602M
YoY Change			-18.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001857044
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale		usd
	INDP	Cash Received For Interest Earned On Deposits CashReceivedForInterestEarnedOnDeposits		usd
	INDP	Lease Renewal Option Exercise LeaseRenewalOptionExercise		usd
	INDP	Reclassification Of Security Deposit ReclassificationOfSecurityDeposit		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity File Number EntityFileNumber	001-40652
	dei	Entity Registrant Name EntityRegistrantName	Indaptus Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3158720
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 Columbus Circle
	dei	Entity Address Address Line2 EntityAddressAddressLine2	15th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	427-2727
	dei	Security12b Title Security12bTitle	Common stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	INDP
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8401047	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15963998	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9626800	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16806009	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	879524	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	811433	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	16843522	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27244242	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1055	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2019	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	194751	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	79294	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	754728	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	738251	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	950534	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	819564	usd
CY2023Q3	us-gaap	Assets Assets	17794056	usd
CY2022Q4	us-gaap	Assets Assets	28063806	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2264062	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3352847	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101004	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	80494	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2365066	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3433341	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95237	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	95237	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2460303	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3433341	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8401047	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8401047	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8401047	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8401047	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	84011	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	84011	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56664118	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54443705	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41414376	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29993685	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	96434	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	15333753	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	24630465	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17794056	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28063806	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2226688	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1609554	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5587073	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4412817	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2021724	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1942995	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6611767	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6411066	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	4248412	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3552549	usd
	us-gaap	Operating Expenses OperatingExpenses	12198840	usd
	us-gaap	Operating Expenses OperatingExpenses	10823883	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4248412	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3552549	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12198840	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10823883	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	326024	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	86184	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	778149	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	156862	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3922388	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466365	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11420691	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10667021	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.29
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8401047	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8401047	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8258597	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8258597	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8401047	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8401047	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8258597	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8258597	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3922388	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466365	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11420691	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10667021	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	140567	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	7836	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	430993	usd
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	7836	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6412	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	49904	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	334559	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22967	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4056543	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3424297	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11517125	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10651890	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35899580	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	831183	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9221	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3365154	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	33356388	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	904395	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-17716	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3835502	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30407565	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	584041	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	7836	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	49904	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466365	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27567309	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	24630465	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	727144	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	129229	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	210252	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4253238	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	21185394	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	728466	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	161197	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	117895	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3245065	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	18625493	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	18625493	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	764803	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	140567	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6412	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3922388	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	15333753	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	15333753	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11420691	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10667021	usd
	us-gaap	Depreciation Depreciation	964	usd
	us-gaap	Depreciation Depreciation	1460	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2220413	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2319619	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	430993	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	7836	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	24155	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	84568	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	26739	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1088785	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1725592	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	738251	usd
	INDP	Increase Decrease In Operating Lease Right Of Use Asset And Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet	290	usd
	INDP	Increase Decrease In Operating Lease Right Of Use Asset And Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet	1081	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10803370	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10867434	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	172555	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	24000000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	2000000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6859432	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23719073	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17140568	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21546518	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6337198	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-32413952	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9626800	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39132165	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15963998	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6718213	usd
	INDP	Cash Received For Interest Earned On Deposits CashReceivedForInterestEarnedOnDeposits	-96434	usd
	INDP	Lease Renewal Option Exercise LeaseRenewalOptionExercise	236506	usd
	INDP	Reclassification Of Security Deposit ReclassificationOfSecurityDeposit	16477	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2400	usd
	INDP	Supplemental Disclosures Cash Received For Interest Earned On Deposits SupplementalDisclosuresCashReceivedForInterestEarnedOnDeposits	317261	usd
	INDP	Supplemental Disclosures Cash Received For Interest Earned On Deposits SupplementalDisclosuresCashReceivedForInterestEarnedOnDeposits	70353	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_808_eus-gaap--NatureOfOperations_zW3Cm6NeuRnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_82C_zhdSpSedTkHl">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the “Company”), is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted product that activates both innate and adaptive anti-tumor and anti-viral immune responses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, the need for additional capital (or financing) to fund operating losses (see below), competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence on key individuals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to general conditions and macroeconomic factors in the global economy including increasing concerns over banking failures and bailouts and their potential broader effect on the banking sector generally and on the biotechnology industry. Additionally, inflation, rising interest rates, overall economic conditions and uncertainties, and the risk of a severe or prolonged economic downturn could result in a variety of risks, including the Company’s ability to raise additional funding on a timely basis or on acceptable terms and may additionally impact third parties upon which the Company relies to carry out its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going concern and management’s plans</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred net losses and utilized cash in operations since inception. For the nine months ended September 30, 2023, the Company incurred a net loss of approximately $<span id="xdx_90A_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230930_zkxPQs9wzbej" title="Net loss">11.4</span> million, and as of September 30, 2023, the Company had an accumulated deficit of approximately $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230930_z4jZgndlq7gd" title="Accumulated deficit">41.4</span> million. In addition, during the nine months ended September 30, 2023, the Company used approximately $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230930_zIGjPANYgTi9" title="Cash in operations">10.8</span> million of cash in operations and expects to continue to incur significant cash outflows and incur future additional losses as clinical trials and commercialization of the Company’s product candidates will require significant additional financing. The Company believes that, as of the date of the issuance of these condensed consolidated financial statements, it will not have adequate cash to fund its ongoing activities beyond the second quarter of 2024 based on its current operating plan. The Company plans to execute its operating plan by obtaining additional capital, principally through entering into collaborations, strategic alliances, or license agreements with third parties and/or additional public or private debt and equity financing. However, there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the Company or in the amounts required. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce, or eliminate its research and development programs, which could adversely affect its business prospects, or cease operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of these uncertainties, there is substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Net Income Loss NetIncomeLoss	-11400000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zik7eXO8In61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z7FR3aS0Dbmh">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and adjusts when facts and circumstances dictate. These estimates are based on information available as of the date of the condensed consolidated financial statements; therefore, actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	INDP	Accrued Board Fees Current AccruedBoardFeesCurrent	116000	usd
CY2023Q3	INDP	Delaware Franchise Taxes Payable Current DelawareFranchiseTaxesPayableCurrent	30000	usd
CY2022Q4	INDP	Delaware Franchise Taxes Payable Current DelawareFranchiseTaxesPayableCurrent	128929	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19963	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29968	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2264062	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3352847	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1672873	shares
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	737881	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	610208	usd
CY2023Q3	INDP	Prepaid Research And Development PrepaidResearchAndDevelopment	19457	usd
CY2022Q4	INDP	Prepaid Research And Development PrepaidResearchAndDevelopment	80910	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	122186	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	120315	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	879524	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	811433	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	617270	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1378316	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	795183	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1216242	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	124852	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	172356	usd
CY2023Q3	INDP	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	559044	usd
CY2022Q4	INDP	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	311036	usd
CY2023Q3	INDP	Accrued Board Fees Current AccruedBoardFeesCurrent	117750	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.01
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	425750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	48426	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.34
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2050197	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.86
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	556523	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1080701	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.37
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	62993	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2050197	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.86
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	556523	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	764803	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	584041	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2220413	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2319619	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3000000.0	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y10M24D
CY2023Q3	INDP	Weighted Average Grant Date Fair Value Of Stock Options WeightedAverageGrantDateFairValueOfStockOptions	1.43
CY2023Q3	us-gaap	Share Price SharePrice	1.70
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.109	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2050197	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8401047	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8401047	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8401047	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8401047	shares
CY2023Q2	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	lease agreement to extend the lease through October 31, 2025.
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	236506	usd
CY2023Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.09	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	25105	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	101705	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	86862	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	213672	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17431	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	196241	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	101004	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95237	usd
	us-gaap	Payments For Rent PaymentsForRent	75280	usd
	us-gaap	Payments For Rent PaymentsForRent	73069	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	25462	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	24356	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	74148	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	71989	usd

Files In Submission

Name	View Source	Status
0001493152-23-039523-index-headers.html	Edgar Link	pending
0001493152-23-039523-index.html	Edgar Link	pending
0001493152-23-039523.txt	Edgar Link	pending
0001493152-23-039523-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
indp-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
indp-20230930_lab.xml	Edgar Link	unprocessable
indp-20230930_cal.xml	Edgar Link	unprocessable
indp-20230930_def.xml	Edgar Link	unprocessable
indp-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INDP
Indaptus Therapeutics, Inc. Stock $indp

2023 Q4 Form 10-Q Financial Statement

#000149315223039523 Filed on November 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INDP Indaptus Therapeutics, Inc. Stock $indp

2023 Q4 Form 10-Q Financial Statement

#000149315223039523 Filed on November 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INDP
Indaptus Therapeutics, Inc. Stock $indp